Designing a Vaccine against Chlamydia
Abstract
The prevention of Chlamydia has been a headache for medical practitioners due to the challenge of finding effective vaccines for the disease. Several researchers have attributed the use of Hepatitis E Viral Nanoparticles (HEVNP) as an effective vaccine design against Chlamydia. Recent developments have been done on Chlamydia vaccines to close the gap that has been causing difficulties in obtaining an amicable vaccine for Chlamydia trachomatis. Some of the developments include engineering of the Capsid protein of the Hepatitis E Viral Nanoparticles where the Hepatitis E Viral Nanoparticles self-assembles into stable icosahedra cage to provide a unique way of obtaining the design for the Chlamydia vaccine. Tests have been done on mice, guinea pigs, and sheep to assess the applicability of the vaccine as a solution to the Chlamydia problem in humans. The tests done on animals have been used to answer questions arising concerning the vaccinology. The study has been based on developing a quicker way of designing Chlamydia vaccines. Also, the study specifies ethical standards that need to be addressed in an attempt to create the vaccine.